Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Abbott's earnings call reflects strong financial performance with double-digit EPS growth and improved margins. Despite slightly lower revenue growth guidance, the company anticipates recovery in the Nutrition segment and sustained growth across other divisions. Positive product developments, particularly in Medical Devices and Diagnostics, coupled with strategic initiatives, bolster a positive outlook. The Q&A session reveals confidence in overcoming short-term challenges and executing long-term growth strategies, contributing to an overall positive sentiment.
Key Financial Performance
Nutrition Sales Declined in the quarter due to market share loss, partly from losing a large weight contract last year. Higher manufacturing costs and price increases have constrained volume growth. Initiatives to reignite volume growth include price and promotion adjustments and increased focus on innovation.
Diagnostics Sales Declined 3.5% due to the anticipated year-over-year decline in COVID testing sales. Core Lab Diagnostics grew 3.5%, with 7% growth excluding China, driven by durable demand globally. Point of Care Diagnostics sales grew 7%, driven by adoption of the high-sensitivity troponin test.
EPD Sales Increased 7% in the quarter, with balanced growth across markets and therapeutic areas. Double-digit growth was noted in India, Latin America, and the Middle East.
Medical Devices Sales Grew 10.5%. Diabetes Care sales of continuous glucose monitors grew 12% in the quarter and 17% for the year, exceeding $7.5 billion in 2025. Electrophysiology, structural heart, and heart failure segments also saw double-digit growth. Rhythm Management grew 12%, and Vascular grew 6.5%.
Adjusted Earnings Per Share (EPS) $1.50, reflecting 12% growth compared to the prior year. Adjusted gross margin increased to 57.1% of sales, up 20 basis points. Adjusted operating margin increased to 25.8% of sales, up 150 basis points.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Regulatory Approvals: Achieved approvals for Volt and TactiFlex Duo PFA products, new indication for Navitor TAVR valve, CMS national coverage for TriClip and CardioMEMS, and filed for FDA approval for dual glucose-ketone sensor.
New Product Launches: Initiated launch sequence for biosimilars in emerging markets and new nutrition products to meet evolving consumer preferences.
Pipeline Development: Completed enrollment in pivotal trial for new LAA device and initiated pivotal trial for coronary IVL device.
Geographic Expansion: EPD achieved double-digit growth in India, Latin America, and the Middle East, focusing on high-demand therapies in faster-growing markets.
Cost Management: Implemented price and promotion initiatives in Nutrition to address volume growth challenges caused by higher manufacturing costs and price sensitivity.
Segment Performance: Core Lab Diagnostics grew 3.5%, Point of Care Diagnostics grew 7%, and Medical Devices grew 10.5% driven by strong performance in diabetes care, electrophysiology, and structural heart.
Acquisition: Announced acquisition of Exact Sciences to enter the cancer diagnostics market and add a high-growth business to the portfolio.
Investment Strategy: Focused on sustaining growth in high-growth segments like diabetes and structural heart while improving foundational segments like Rhythm Management and Vascular.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
U.S. Pediatric Nutrition Business: The business is facing challenges due to market share loss, partly from losing a large WIC contract last year. Additionally, there is a broader challenge of reigniting volume growth, exacerbated by increased manufacturing costs and price sensitivity among consumers. This dynamic is suppressing demand and impacting near-term results.
COVID Testing Sales: Sales in Diagnostics declined 3.5% due to the anticipated year-over-year decline in COVID testing sales, which has been a significant revenue driver in the past.
China Market Challenges: Heightened market challenges in China have impacted overall performance, particularly in the Diagnostics and Nutrition segments.
Manufacturing Costs in Nutrition: Post-pandemic-driven surge in commodity costs has led to higher manufacturing costs in the Nutrition segment. Price increases to offset these costs are constraining volume growth as consumers become more price-sensitive.
Economic Environment: The current economic environment, characterized by price sensitivity among consumers, is impacting demand across various segments, particularly Nutrition.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Organic Sales Growth: Forecasted midpoint of organic sales growth range is 7%.
2026 Adjusted Earnings Per Share: Midpoint of adjusted earnings per share range reflects 10% growth.
Nutrition Segment Outlook: Performance expected to remain challenged in the first half of 2026, with a return to growth in the second half. Plans to launch at least 8 new products over the next 12 months to drive volume growth.
Diagnostics Segment Outlook: Core Lab Diagnostics growth expected to continue building momentum into 2026. Anticipated approval of coronary IVL device next year to drive growth in Vascular segment.
Medical Devices Segment Outlook: Investments in high-growth segments like diabetes, structural heart, electrophysiology, and heart failure expected to sustain strong performance. Rhythm Management and Vascular segments expected to see growth acceleration with new product approvals and market share gains.
Foreign Exchange Impact: Expected favorable impact of around 1% on full-year reported sales, including a 3% favorable impact on first-quarter reported sales.
Adjusted Tax Rate: Forecasted to be in the range of 15% to 16% for 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is Abbott guiding lower revenue growth compared to the previous consensus?
A:Abbott's revenue growth guidance is 0.5% lower than the previous consensus due to challenges in the Nutrition business. The company faced suppressed demand and lower volume growth in Q4 as consumers became more price-sensitive. Abbott has implemented price promotion initiatives and is launching new products to address these challenges, expecting growth in Nutrition to return in the second half of the year.
Q:What is Abbott's strategy for its Electrophysiology (EP) portfolio?
A:Abbott has developed a comprehensive strategy for its EP portfolio, including launching PFA products like Volt and TactiFlex Duo. The company emphasizes providing a toolbox approach for physicians with a complete portfolio, including RF and PFA products, diagnostic elements, and an LAA device. Abbott expects its EP business to grow at least in line with the market, which is forecasted to grow in the mid- to high-teens.
Q:How does Abbott approach its 2026 guidance and risk adjustments?
A:Abbott targets high single-digit top-line growth and double-digit bottom-line growth for 2026. The company expects sustained growth in cardiovascular, diabetes, and EPD businesses, acceleration in diagnostics due to lapping headwinds, and a short-term transition in Nutrition. The Exact Sciences acquisition is also expected to contribute significantly to growth.
Q:What is Abbott's outlook for its Continuous Glucose Monitoring (CGM) business?
A:Abbott expects its CGM business to grow by approximately $1 billion annually, reaching low to mid-teens growth in 2026. The company sees significant opportunities for market penetration across all patient groups and geographies, including non-insulin users. Abbott is also preparing for potential reimbursement expansion in the U.S. for non-insulin users.
Q:What is the status and outlook for Abbott's AVEIR pacemaker?
A:AVEIR is about 10% penetrated in the global low voltage pacing market, which is approximately $5 billion. Abbott sees significant growth opportunities, particularly in the U.S. single-chamber pacing market, which is about 50% penetrated. The company is focused on establishing AVEIR as the next standard in CRM with continued product launches and investments.
Q:What is Abbott's approach to capital allocation and M&A?
A:Abbott remains focused on integrating the Exact Sciences acquisition and prioritizing MedTech and Diagnostics for M&A opportunities. The company does not see a need for inorganic growth in its Nutrition business, as it believes the current strategy will reignite volume growth.
Q:What is Abbott's strategy for its Nutrition business?
A:Abbott is addressing challenges in its Nutrition business by implementing price promotion initiatives and launching new products to drive volume growth. The company expects a short-term impact on growth but anticipates a return to positive growth in the second half of the year.
Q:What is Abbott's outlook for its Diagnostics business, particularly in China?
A:Abbott expects mid-single-digit growth in its Diagnostics business in 2026, with acceleration outside of China. The company has addressed challenges in China, including VBP impacts, and expects stability in the region. Growth in other geographies, such as the U.S., Latin America, and Europe, is expected to drive overall performance.
Q:What is Abbott's outlook for its Structural Heart business?
A:Abbott sees significant growth opportunities in its Structural Heart business, driven by new products like Navitor, TriClip, and Amulet, as well as guideline changes and international expansion. The company is also investing in its pipeline, including next-generation technologies and clinical trials for balloon TAVR and transfemoral transseptal mitral valve replacement.
Q:What is Abbott's view on the macro procedure environment for MedTech?
A:Abbott reports strong volumes across all MedTech categories in Q4 and does not see evidence of slowing procedure volumes. The company remains optimistic about the long-term growth potential of the MedTech sector.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timing of regulatory approvals for the GKS sensor and the potential reimbursement expansion for non-insulin users in the CGM market. Additionally, while they expressed confidence in the Nutrition business strategy, they did not provide precise data on the expected impact of price promotion initiatives or the timeline for achieving volume growth targets.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AFib heart
AFib trial
AVEIR
Amulet
CGM
Care
Diagnostics sale
EPD sale
FDA approval
IVL device
Lab Diagnostics
Medical Devices
Navitor
Nutrition
PFA product
Rhythm market
TactiFlex Duo
TriClip
Vascular digit
approval Volt
consumer good
detection heart
digit share
future
good business
launch sequence
loss
manufacturing price
midpoint
milestone
patient AFib
position
return
step
success
time
ABT Transcript
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Positive1-22
Abbott's earnings call reflects strong financial performance with double-digit EPS growth and improved margins. Despite slightly lower revenue growth guidance, the company anticipates recovery in the Nutrition segment and sustained growth across other divisions. Positive product developments, particularly in Medical Devices and Diagnostics, coupled with strategic initiatives, bolster a positive outlook. The Q&A session reveals confidence in overcoming short-term challenges and executing long-term growth strategies, contributing to an overall positive sentiment.
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Positive10-15
The earnings call summary and Q&A indicate strong growth prospects in diabetes care and heart failure, with positive developments in new product launches like the dual-analyte sensor and AVEIR pacemaker. Despite headwinds in diagnostics and China's market, the company's strategic focus on innovation and expansion in high-growth segments like Structural Heart and EP suggest a positive outlook. However, the lack of detailed guidance on CMS coverage and tariff impacts introduces some uncertainty, but overall, the sentiment leans towards a positive stock price movement.
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Positive7-17
Abbott's earnings call highlights strong financial performance, with high single-digit sales growth and double-digit EPS growth. The company is optimistic about future growth, driven by new product developments and market opportunities. Despite some headwinds, such as reduced COVID testing sales and challenges in China, Abbott is strategically positioned for continued success. The positive sentiment from analysts during the Q&A session reinforces this outlook, particularly in diabetes, CRM, and biosimilars. Overall, the sentiment leans positive, with potential for stock price appreciation in the near term.
Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Call Transcript
Unknown4-18
The earnings call presents a mixed picture. Strong financial metrics, such as EPS growth and gross margin expansion, are positive. However, the lack of a share repurchase program and challenges like tariffs and competitive pressures weigh negatively. The Q&A reveals management's optimism about new product launches but also highlights uncertainties, particularly around tariffs and vague M&A plans. The overall sentiment is balanced by both positive growth indicators and potential risks, leading to a neutral prediction for stock price movement.
ABT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
